Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director | November 21, 2024 | November 25, 2024 |
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 24, 2026 | June 26, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | EVP, Chief Medical Officer | May 07, 2021 | May 11, 2021 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, R&D and CMO | March 05, 2018 | March 07, 2018 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Chief Medical Officer | February 01, 2023 | February 02, 2023 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
| Skye Bioscience, Inc.SKYE · Entity 8098 | Director | March 31, 2026 | April 02, 2026 |
| Tourmaline Bio, Inc.TALS · Entity 15643 | Director | June 13, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date November 21, 2024 · Filed November 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,807 |
Reported balance
After 2024-11-21 transaction · row 1
1 source rowRow 1 · 2024-11-21 · Grant · Acquired 12,135 · Balance 24,807 F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.24 · Expires 2034-11-21 | Direct | 18,641 |
Reported balance
After 2024-11-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-21 · Grant · Acquired 18,641 · Balance 18,641 F2: The options shall vest one year from date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of Restricted Stock Units (RSUs) payable solely in common shares of the Issuer. The shares subject to the RSUs shall vest one year from date of grant.
F2: The options shall vest one year from date of grant.
Context Therapeutics Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-06-23 | Direct | 45,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 45,000 · Balance 45,000 F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 24, 2027 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2027 annual meeting of stockholders, subject to continued service with the Issuer.
Emergent BioSolutions Inc.
Report date May 07, 2021 · Filed May 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,888 |
Reported balance
After 2021-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-07 · Tax withholding · Disposed 305 · Balance 11,888 F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to pay taxes upon vest of restricted stock units granted under the company's stock incentive plan, as amended and restated.
Jazz Pharmaceuticals plc
Report date March 05, 2018 · Filed March 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 28,474 |
Reported balance
After 2018-03-05 transaction · row 1
1 source rowRow 1 · 2018-03-05 · Tax withholding · Disposed 648 · Balance 28,474 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Quince Therapeutics, Inc.
Report date February 01, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.94 · Expires 2033-01-31 | Direct | 225,000 |
Reported balance
After 2023-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-01 · Grant · Acquired 225,000 · Balance 225,000 F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the vesting commencement date of January 1, 2023, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,100 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 102,100 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Skye Bioscience, Inc.
Report date March 31, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2036-03-31 | Direct | 75,000 |
Reported balance
After 2026-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-31 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in equal monthly installments over the one year period beginning March 31, 2026.
Tourmaline Bio, Inc.
Report date June 13, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.54 · Expires 2033-06-13 | Direct | 20,500 |
Reported balance
After 2023-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-13 · Grant · Acquired 20,500 · Balance 20,500 F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACCELERON PHARMA INC
Report date November 19, 2021 · Filed November 22, 2021
Section 16 reporting ended · disclosed 2021-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Other · Disposed 1,622 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $35.34 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $40.61 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 1,875 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $41.64 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 3,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $52.99 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 4,085 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $115.53 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 3,222 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. ("Parent"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 19, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option.
ANTARES PHARMA, INC.
Report date May 24, 2022 · Filed May 26, 2022
Section 16 reporting ended · disclosed 2022-05-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-24 · Disposition to issuer · Disposed 54,193 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-24 · Disposition to issuer · Disposed 25,452 · Balance 0 F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.72 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-24 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-24 · Disposition to issuer · Disposed 46,729 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.73 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-24 · Disposition to issuer · Disposed 58,246 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.42 | Direct | 0 |
Reported balance
After 2022-05-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-24 · Disposition to issuer · Disposed 48,542 · Balance 0 F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 12, 2022, by and among the Issuer, Antares Pharma, Inc., a Delaware corporation (the "Company"), Halozyme Therapeutics, Inc., a Delaware corporation ("Parent"), and Atlas Merger Sub, Inc., a Delaware corporation ("Purchaser") and a wholly owned subsidiary of Parent, to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.01 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 24, 2022 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each Share outstanding immediately prior to the Effective Time (other than Excluded Shares) was converted into the right to receive $5.60 in cash, without interest (the "Merger Consideration") and subject to any withholding of taxes required by applicable legal requirements, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F3: Each Company restricted stock unit ("Company RSU") means any restricted stock unit granted under the Company Equity Plan. At the Effective Time, each Company RSU that was outstanding immediately prior to the Effective Time was cancelled at the Effective Time and converted into the right to receive a cash payment equal to the product of (i) the number of Shares issuable in settlement of the Company RSU immediately prior to the Effective Time multiplied by (ii) the Merger Consideration.
F4: Each Company option to purchase Shares ("Company Option") means any option to purchase Shares granted under the Company Equity Plan. At the Effective Time, each Company Option that was then outstanding as of immediately prior to the Effective Time was, to the extent unvested, accelerated and became fully vested and exercisable effective prior to the Effective Time. Each Company Option that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and converted into the right to receive cash in an amount equal to the product of (i) the total number of Shares subject to such Company Option immediately prior to the Effective Time, multiplied by (ii) the excess of (A) the Merger Consideration over (B) the exercise price payable per Share under such Company Option.
Sucampo Pharmaceuticals, Inc.
Report date February 13, 2018 · Filed February 13, 2018
Section 16 reporting ended · disclosed 2018-02-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.95 · Expires 2027-07-15 | Direct | 0 |
Reported balance
After 2018-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-13 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 05, 2021 Filed Apr 5, 2021 20:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 11,223 | $140.13 | $1,572,678.99 |
DisclosureSEC source: 0001179110-21-004223 · edgar.xml · nonDerivative · entry 4 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,263 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.00 to $140.92 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 20:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 2,050 | $52.99 | $108,629.50 |
DisclosureSEC source: 0001179110-21-004223 · edgar.xml · nonDerivative · entry 3 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 20:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 1,875 | $41.64 | $78,075.00 |
DisclosureSEC source: 0001179110-21-004223 · edgar.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 20:17 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 5,000 | $35.34 | $176,700.00 |
DisclosureSEC source: 0001179110-21-004223 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 2,050 | $0.00 Strike: $52.99 | $0.00 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · derivative · entry 10 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,135 Underlying: Common Stock · 2,050 shares Expires 2030-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 1,875 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · derivative · entry 9 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,875 shares Expires 2029-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in full on the one year anniversary of the grant date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionOption to Purchase Common Stock · Derivative | 5,000 | $0.00 Strike: $35.34 | $0.00 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · derivative · entry 8 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires 2027-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 941 | $137.92 | $129,782.72 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 7 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.77 to $138.16 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 3,796 | $136.92 | $519,748.32 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 6 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,502 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.74 to $137.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 2,987 | $136.22 | $406,889.14 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 5 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,298 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.72 to $136.64 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | SaleCommon Stock | 1,201 | $134.54 | $161,582.54 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 4 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,285 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.10 to $135.05 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 2,050 | $52.99 | $108,629.50 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 3 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 1,875 | $41.64 | $78,075.00 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 18:00 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | Exercise / conversionCommon Stock | 5,000 | $35.34 | $176,700.00 |
DisclosureSEC source: 0001179110-21-004119 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 16,400 | $0.00 Strike: $11.19 | $0.00 |
DisclosureSEC source: 0001209191-21-015513 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2031-02-24 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 8,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-015513 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,700 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · balance_after: Includes: (a) 1,667 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing the final remaining vesting tranche from such RSU grant with such RSUs vesting on June 26, 2021; and (b) 10,000 shares of common stock issuable upon settlement of RSUs subject to Reporting Person's May 18, 2020 RSU grant that will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the Issuer's 2021 annual stockholders meeting. The vesting of all such RSUs is subject to the Reporting Person's Continuous Service as defined in the 2018 EIP, as amended, through such dates and subject to acceleration as defined in the 2018 EIP, as amended. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Options (Right to Buy) · Derivative | 11,765 | $93.49 Strike: $93.49 | $1,099,909.85 |
DisclosureSEC source: 0001367644-21-000044 · wf-form4_161437771751742.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,765 Underlying: Common Stock · 11,765 shares Expires 2028-02-23 F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000044 · wf-form4_161437771751742.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,193 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2021 and ending December 31, 2023, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 22:15 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,942 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-21-000044 · wf-form4_161437771751742.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,252 F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:52 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 3,222 | $0.00 Strike: $115.53 | $0.00 |
DisclosureSEC source: 0001179110-21-001113 · edgar.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,222 Underlying: Common Stock · 3,222 shares Expires 2031-01-29 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 18:52 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001113 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,561 Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:15 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 58,246 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001209191-20-036849 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,246 Underlying: Common Stock · 58,246 shares Expires 2030-06-11 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:15 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 30,220 | $2.73 | $82,500.60 |
DisclosureSEC source: 0001209191-20-036849 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,193 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-030965 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-17 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:21 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030965 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021, (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. F2 · balance_after: Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant. Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such dates. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:30 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $10.46 | $0.00 |
DisclosureSEC source: 0001209191-20-034029 · doc4a.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-17 F4 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended). The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Continuous Service (as defined in the 2018 EIP, as amended) over the 12-month period measured from the grant date and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| May 18, 2020 Filed Jun 3, 2020 20:30 UTC Amendment | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034029 · doc4a.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) May 18, 2021 (the first anniversary of the date of grant) or (y) the day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP, as amended")), through such date and subject to acceleration as provided in the 2018 EIP, as amended. F2 · shares: This Form 4/A is being filed solely to correct the stated grant amounts which were erroneously reported on Form 4 filed on behalf of the Reporting Person on May 20, 2020. Pursuant to the 2018 EIP, as amended, and the Automatic Grant Program for Non-Employee Directors thereunder, the annual grant amounts increased effective with the approval of the 2018 EIP, as amended, by the stockholders of the Issuer on May 18, 2020. Such previously filed Form 4 incorrectly stated grant amounts pursuant to the Automatic Grant Program for Non-Employee Directors prior to such amendment and restatement of the 2018 Equity Incentive Plan. F3 · balance_after: Includes 3,333 shares of common stock issuable upon settlement of RSUs granted to the Reporting Person on June 26, 2018 representing two remaining vesting tranches from such RSU grant. Such RSUs vest with respect to 1,666 shares on June 26, 2020 and 1,667 shares on June 26, 2021, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP, as amended) through such dates and subject to acceleration as provided in the 2018 EIP, as amended. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 19:32 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 8,185 | $0.00 Strike: $52.99 | $0.00 |
DisclosureSEC source: 0001179110-20-000790 · edgar.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,185 Underlying: Common Stock · 8,185 shares Expires 2030-01-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 19:32 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000790 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,939 Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:51 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 46,729 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001209191-19-037257 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,729 Underlying: Common Stock · 46,729 shares Expires 2029-06-13 F2 · shares: Represents grant of options to purchase shares of common stock, par value $0.01 per share, issued under the Antares Pharma, Inc. Equity Compensation Plan. F3 · derivative.exercise_date: The options vest and become exercisable one year from the grant date. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:51 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantCommon Stock | 23,973 | $2.92 | $70,001.16 |
DisclosureSEC source: 0001209191-19-037257 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,973 F1 · shares: Represents grant of restricted stock units made under the Antares Pharma, Inc. Equity Compensation Plan. The shares vest one year from the grant date. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.38 | $0.00 |
DisclosureSEC source: 0001209191-19-036443 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F3 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:09 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036443 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. F2 · balance_after: Includes 5,000 shares of common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person on June 26, 2018. The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:02 UTC | ANTARES PHARMA, INC. ATRS · Entity 126887 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001209191-19-016881 · doc4.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-03-01 F1 · shares: Represents initial grant of options, given to each director upon becoming a member of the board of directors, to purchase shares of common stock, par value of $0.01 per share, issued under the Antares Pharma, Inc. 2008 Equity Compensation Plan. F2 · derivative.exercise_date: The options vest in equal quarterly installments over three years from the date of grant. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 7,500 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001179110-19-001064 · edgar.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-01-25 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| January 25, 2019 Filed Jan 29, 2019 17:49 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001064 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562 Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:33 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001209191-18-039973 · doc4.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-25 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 23:33 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-039973 · doc4.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 648 | $143.39 | $92,916.72 |
DisclosureSEC source: 0001232524-18-000062 · edgardoc.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,474 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 1,875 | $0.00 Strike: $40.61 | $0.00 |
DisclosureSEC source: 0001179110-18-003511 · edgar.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875 Underlying: Common Stock · 1,875 shares Expires 2028-03-01 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in full on the one year anniversary of the grant date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 17:23 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantCommon Stock | 312 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-003511 · edgar.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 19,290 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000046 · edgardoc.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,290 Underlying: Ordinary Shares · 19,290 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 710 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000046 · edgardoc.xml · derivative · entry 2 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710 Underlying: Ordinary Shares · 710 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:30 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000046 · edgardoc.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,122 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 525 | $147.44 | $77,406.00 |
DisclosureSEC source: 0001232524-18-000029 · edgardoc.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,122 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 59 ordinary shares acquired on May 31, 2017 and 61 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| February 13, 2018 Filed Feb 13, 2018 16:56 UTC | Sucampo Pharmaceuticals, Inc. SCMP · Entity 169352 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 30,000 | $7.05 Strike: $10.95 | $211,500.00 |
DisclosureSEC source: 0001171843-18-001109 · formfour.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-07-15 F1 · derivative.exercise_date: This option was cancelled and converted into the right to receive in cash the amount per share by which $18.00 exceeds the exercise price of the option, subject to any applicable tax witholdings (such amount, the "Option Spread"), upon the effective time of the merger of Sun Acquisition Co.with and into Sucampo Pharmaceuticals, Inc. pursuant to the Merger Agreement. The Option Spread for the unvested portion of the option, if any, will be paid in accordance with the schedule described in the Merger Agreement. Read SEC document |
| November 15, 2017 Filed Nov 15, 2017 16:22 UTC | ACCELERON PHARMA INC XLRN · Entity 15780 | GrantOption to Purchase Common Stock · Derivative | 20,000 | $0.00 Strike: $35.34 | $0.00 |
DisclosureSEC source: 0001179110-17-014159 · edgar.xml · derivative · entry 1 Smith Karen L. · CIK 0001639637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-11-15 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award vest in equal quarterly installments over the first three years after the grant. Read SEC document |
| May 11, 2017 Filed May 13, 2017 00:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $155.18 | $0.00 |
DisclosureSEC source: 0001639637-17-000004 · edgardoc.xml · derivative · entry 3 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires 2027-05-10 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, May 11, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 11, 2017 Filed May 13, 2017 00:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001639637-17-000004 · edgardoc.xml · nonDerivative · entry 2 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,527 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of June 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| May 11, 2017 Filed May 13, 2017 00:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 641 | $155.18 | $99,470.38 |
DisclosureSEC source: 0001639637-17-000004 · edgardoc.xml · nonDerivative · entry 1 Smith Karen L. · CIK 0001639637 · EVP, R&D and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,527 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.